The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Let the traders get there few % that’s the market and that needs to be accepted.
The MC needs / will rerate and will be multiples of the current.
Some will gain a few % some will gain hundreds.
Is what it is….
As ever it’s hard to buy - they will need to let it run at some point…. Better be sitting in 3’s before news
Yeah being held back imo - any small purchase will move this. 200ma broken
Its on the cusp of breaking this and surpassing it.....BULLISH
Really wouldn't surprise me if news landed next week after a big week of conferences as well as a trading update due in May
Past two Fridays we have seen position taking with a little bit of volume….lets see if people will try get ahead of the curve today
There is also FA stock about - will move north on nothing, it takes out 1.50 then it’s a bit of blue sky to 2
Morning,
Ant - very speculative I know but you do seem very educated in the field and as myself and others have mentioned your opinion is very much valued and it’s great to see.
Additional consulting contracts aside, how do you see the dosing tool potentially (if approved) rolling out.
Obviously these is the DoseMe Link/potential
Then there is The UK and Europe side.
I previously outlined my thoughts on the DoseMe connection…
Would be interested to see your view
cheers
KHJ
Happened last Friday also - wouldn't say this is a pump and dump unless people are looking for beer money returns based on the actual volume.
Also significant reduced costs moving forward as per all the recent presentations
The active recruitment drive for numerous roles would
Indicate the work load is increasing on many fronts
Seem to do the same last Friday if I remember then fell Monday - traders looking for 0.1% lol
I would also like to second Trench’s Post.
Ant your contribution are brilliant and very much welcomed.
I have been invested in PYC for many many many years and the personalised dosing tool as stated numerous times could / should have huge commercial value.
I could be wrong but my understanding although there is numerous way it could be rolled out if approved that the technology would be integrated to Dosemerx and PYC would get a fee for this tech per license of which DoseMe has hundreds of thousand licenses in hospitals, surgery’s, universities and practises world wide !!!
This in mind the potential is exponential before you look at the UK (NHS) and European market
Correct De Bull - its was founded and started in Australia.
Doseme was acquired by Tabula Rasa Health Care for £20 Million Dollars
Tabula Rasa then got rid of the assets as it wasn't a core one and wasn't generating any cash - they eventually sold this for £1.5 Million making a significant Multi million lost
Can’t see any ramping tbh but valid point. Spread awful has been for a while was 30% a few days ago
Brilliant Post Ant - Thank You
Great post this ANT
Good Post Brighty
Agree in your statements - I mean the last presentation stated a £1m pipeline then the interims last week stated £1.5 m pipeline so it would indicate there is significant growth forecasted
You mean the 1.5 M revenues as per the interims results
The Directors believe the Company will continue to trade in line with market expectations.
Surely this is a 1.5Million pipeline therefore profitable by a few hundred k
The Company's pipeline of potential new business now stands at over £1.5m
How has Suzy dodged this one…..her role needs to be up there for a vote aswell…… maybe she knows the other three and has oceatrated the whole thing….. more time more money rinsed - smoke and mirrors - absolute scammers